IE911831A1 - Process for the preparation of derivatives of growth hormone¹releasing factor and peptides useful as intermediates in the¹process - Google Patents
Process for the preparation of derivatives of growth hormone¹releasing factor and peptides useful as intermediates in the¹processInfo
- Publication number
- IE911831A1 IE911831A1 IE183191A IE183191A IE911831A1 IE 911831 A1 IE911831 A1 IE 911831A1 IE 183191 A IE183191 A IE 183191A IE 183191 A IE183191 A IE 183191A IE 911831 A1 IE911831 A1 IE 911831A1
- Authority
- IE
- Ireland
- Prior art keywords
- grf
- ser
- commun
- ala
- breddam
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims abstract description 42
- 230000008569 process Effects 0.000 title claims abstract description 30
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000000543 intermediate Substances 0.000 title abstract description 9
- 101710142969 Somatoliberin Proteins 0.000 claims abstract description 76
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims abstract description 59
- 239000000758 substrate Substances 0.000 claims abstract description 48
- 102000004190 Enzymes Human genes 0.000 claims abstract description 38
- 108090000790 Enzymes Proteins 0.000 claims abstract description 38
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 13
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 12
- 108010053803 Sermorelin Proteins 0.000 claims abstract description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 11
- 230000008878 coupling Effects 0.000 claims abstract description 10
- 238000010168 coupling process Methods 0.000 claims abstract description 10
- 238000005859 coupling reaction Methods 0.000 claims abstract description 10
- 239000007864 aqueous solution Substances 0.000 claims abstract description 7
- 239000012634 fragment Substances 0.000 claims abstract description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 6
- 241001465754 Metazoa Species 0.000 claims abstract description 5
- 125000002015 acyclic group Chemical group 0.000 claims abstract description 5
- 230000000813 microbial effect Effects 0.000 claims abstract description 5
- 235000013311 vegetables Nutrition 0.000 claims abstract description 5
- 239000006185 dispersion Substances 0.000 claims abstract description 4
- 102100022831 Somatoliberin Human genes 0.000 claims abstract 20
- 238000006243 chemical reaction Methods 0.000 claims description 70
- 239000012038 nucleophile Substances 0.000 claims description 39
- 102000005572 Cathepsin A Human genes 0.000 claims description 35
- 108010059081 Cathepsin A Proteins 0.000 claims description 35
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 31
- 102000005367 Carboxypeptidases Human genes 0.000 claims description 26
- 108010006303 Carboxypeptidases Proteins 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- -1 benzylsuccinyl groups Chemical group 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 229920005989 resin Polymers 0.000 claims description 9
- 239000011347 resin Substances 0.000 claims description 9
- 102000035195 Peptidases Human genes 0.000 claims description 7
- 108091005804 Peptidases Proteins 0.000 claims description 7
- KFGRVLINLVVMJA-MITYVQBRSA-N chembl440262 Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=C(O)C=C1 KFGRVLINLVVMJA-MITYVQBRSA-N 0.000 claims description 7
- 235000019833 protease Nutrition 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 150000007513 acids Chemical class 0.000 claims description 5
- 108010056001 somatotropin releasing hormone (1-29) Proteins 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- 244000099147 Ananas comosus Species 0.000 claims description 2
- 235000007119 Ananas comosus Nutrition 0.000 claims description 2
- 244000241235 Citrullus lanatus Species 0.000 claims description 2
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 claims description 2
- 241001561395 Citrus natsudaidai Species 0.000 claims description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 2
- 240000002024 Gossypium herbaceum Species 0.000 claims description 2
- 235000004341 Gossypium herbaceum Nutrition 0.000 claims description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 2
- 241000228129 Penicillium janthinellum Species 0.000 claims description 2
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 2
- 240000003768 Solanum lycopersicum Species 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 238000013459 approach Methods 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000002952 polymeric resin Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 229920003002 synthetic resin Polymers 0.000 claims description 2
- 235000015099 wheat brans Nutrition 0.000 claims description 2
- 240000006439 Aspergillus oryzae Species 0.000 claims 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims 1
- 241000228251 Aspergillus phoenicis Species 0.000 claims 1
- 240000005979 Hordeum vulgare Species 0.000 claims 1
- 235000007340 Hordeum vulgare Nutrition 0.000 claims 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- ULEBESPCVWBNIF-BYPYZUCNSA-N L-arginine amide Chemical compound NC(=O)[C@@H](N)CCCNC(N)=N ULEBESPCVWBNIF-BYPYZUCNSA-N 0.000 abstract description 12
- 150000001408 amides Chemical class 0.000 abstract description 8
- 101000978265 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Carboxypeptidase Y Proteins 0.000 abstract 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 57
- 235000001014 amino acid Nutrition 0.000 description 43
- 150000001413 amino acids Chemical class 0.000 description 41
- 229940088598 enzyme Drugs 0.000 description 37
- 239000000047 product Substances 0.000 description 37
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 26
- 230000015572 biosynthetic process Effects 0.000 description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 14
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 108010059841 serine carboxypeptidase Proteins 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 11
- 230000009435 amidation Effects 0.000 description 10
- 238000007112 amidation reaction Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 210000004899 c-terminal region Anatomy 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 239000006227 byproduct Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 108010005991 Pork Regular Insulin Proteins 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 229960001484 edetic acid Drugs 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 230000035484 reaction time Effects 0.000 description 6
- 241000024188 Andala Species 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 239000012429 reaction media Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108700023418 Amidases Proteins 0.000 description 3
- 108010059378 Endopeptidases Proteins 0.000 description 3
- 102000005593 Endopeptidases Human genes 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102000005922 amidase Human genes 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000007859 condensation product Substances 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000007056 transamidation reaction Methods 0.000 description 3
- PPFRJEXUPZWQPI-JTQLQIEISA-N (2s)-2-benzamido-4-methylsulfanylbutanoic acid Chemical compound CSCC[C@@H](C(O)=O)NC(=O)C1=CC=CC=C1 PPFRJEXUPZWQPI-JTQLQIEISA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229910014033 C-OH Inorganic materials 0.000 description 2
- 102400000107 C-terminal peptide Human genes 0.000 description 2
- 229910014570 C—OH Inorganic materials 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 108010004237 Glycine oxidase Proteins 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 2
- 150000008575 L-amino acids Chemical group 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 229940066758 endopeptidases Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 239000003668 hormone analog Substances 0.000 description 2
- 229940045644 human calcitonin Drugs 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- UBLQIESZTDNNAO-UHFFFAOYSA-N n,n-diethylethanamine;phosphoric acid Chemical compound [O-]P([O-])([O-])=O.CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC UBLQIESZTDNNAO-UHFFFAOYSA-N 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000011191 terminal modification Methods 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- PZUOEYPTQJILHP-GBXIJSLDSA-N (2s,3r)-2-amino-3-hydroxybutanamide Chemical compound C[C@@H](O)[C@H](N)C(N)=O PZUOEYPTQJILHP-GBXIJSLDSA-N 0.000 description 1
- BHLMPCPJODEJRG-UHFFFAOYSA-N 2,6-diaminohex-4-ynoic acid Chemical compound NCC#CCC(N)C(O)=O BHLMPCPJODEJRG-UHFFFAOYSA-N 0.000 description 1
- MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 description 1
- VUCNQOPCYRJCGQ-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenoxy]acetic acid Chemical compound OCC1=CC=C(OCC(O)=O)C=C1 VUCNQOPCYRJCGQ-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- CUVGUPIVTLGRGI-UHFFFAOYSA-N 4-(3-phosphonopropyl)piperazine-2-carboxylic acid Chemical compound OC(=O)C1CN(CCCP(O)(O)=O)CCN1 CUVGUPIVTLGRGI-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 101800000736 Growth hormone-releasing factor Proteins 0.000 description 1
- 101710119601 Growth hormone-releasing peptides Proteins 0.000 description 1
- 101000825742 Homo sapiens Somatoliberin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- FORGMRSGVSYZQR-YFKPBYRVSA-N L-leucinamide Chemical compound CC(C)C[C@H](N)C(N)=O FORGMRSGVSYZQR-YFKPBYRVSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical group NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- NSTPXGARCQOSAU-VIFPVBQESA-N N-formyl-L-phenylalanine Chemical compound O=CN[C@H](C(=O)O)CC1=CC=CC=C1 NSTPXGARCQOSAU-VIFPVBQESA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- ZKQOUHVVXABNDG-IUCAKERBSA-N Pro-Leu Chemical group CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 ZKQOUHVVXABNDG-IUCAKERBSA-N 0.000 description 1
- IWIANZLCJVYEFX-RYUDHWBXSA-N Pro-Phe Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 IWIANZLCJVYEFX-RYUDHWBXSA-N 0.000 description 1
- AWJGUZSYVIVZGP-YUMQZZPRSA-N Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 AWJGUZSYVIVZGP-YUMQZZPRSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101710097834 Thiol protease Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000012431 aqueous reaction media Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 108010054847 carboxypeptidase P Proteins 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 description 1
- 235000005489 dwarf bean Nutrition 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- GDYWLOSEHSCOED-NSHDSACASA-N methyl (2s)-2-benzamido-4-methylsulfanylbutanoate Chemical compound CSCC[C@@H](C(=O)OC)NC(=O)C1=CC=CC=C1 GDYWLOSEHSCOED-NSHDSACASA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000000819 phase cycle Methods 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- ROIUYVCORDXOOK-GJZGRUSLSA-N propan-2-yl (2s)-2-[[(2s)-2-benzamido-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoate Chemical compound CC(C)OC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)C1=CC=CC=C1 ROIUYVCORDXOOK-GJZGRUSLSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/16—Serine-type carboxypeptidases (3.4.16)
- C12Y304/16005—Carboxypeptidase C (3.4.16.5), i.e. carboxypeptidase Y
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Derivatives of growth hormone releasing factor GRF(1-29)NH2 and analogs thereof, are prepared by reacting a substrate component of the formula GRF'-Met-Ser-X, wherein GRF' denominates the native GRF(1-26) sequence or analogs thereof including GRF(n-26) fragments, where n is from 1 to 8, and X is an acyclic alpha -amino carboxylic acid residue having an uncharged hydrophilic side chain of at least the size of a methyl group, preferably Ala, Thr, Ser, Asn or Gln, with H-Arg-NH2 as mucleophile component in the presence of an L-specific serine or thiolcarboxypeptidase enzyme from yeast or of animal, vegetable or other microbial origin, preferably CPD-Y from yeast, in an aqueous solution or dispersion having a pH of from 6 to 9, and if necessary coupling the desired N-terminal (1-(n-1)) fragment chemically or enzymatically. GRF-related peptides of the formula GRF"-Met-Ser-X, wherein GRF" denominates the native GRF(1-26) sequence, wherein from 1 to 4 amino acid residues may be replaced or deleted or the des- alpha -NH2 derivatives thereof, and X is as described above and useful intermediates. The process enables a selective transpeptidation leading to biologically active GRF-related amides in good yields.
Description
Process for the preparation of derivatives of growth hormone releasing factor and peptides useful as intermediates in the process
The present invention relates to. a process for the preparation of GRF(1-29)NH2, an interesting biologically active derivative of growth hormone releasing factor, and analogs thereof as well as new peptides which are useful as intermediates in this process.
The use of biologically active peptides for pharmaceutical purposes and in agriculture has increased the importance of being able to synthesize such compounds in bulk-scale.
Three methods are available: (a) chemical synthesis, (b) enzymatic synthesis, and (c) fermentation with genetically manipulated microorganisms. While the methods (a) and (b), or a combination of them, are the preferred for short peptides it becomes more and more apparent that long peptides in the future will be produced through exploitation of the advances in the methods dealing with recombinant DNA. However, these methods do not permit a number of modications such as incorporation of D-amino acids and Cterminal amide groups which may be of importance for the biological activity. A subsequent enzymatic modification is therefore highly desirable and such reactions have only been studied to a limited extent.
An enzyme has been described which catalyses the hydroxyl30 ation of C-terminal glycyl residues which subsequently decomposes leaving the penultimate residue amidated (US Patent No. 4.708.934, EP 308067A, DK Application No. 4489/88). This glycine oxidase enzyme which is dependent on Cu^+, 02 and ascorbate as cofactors is considered to be the enzyme responsible for in vivo formation of peptide amides. It has been utilised for amidation of peptides in small scale but as it exhibits low activity its applicability for large scale work is still questionable. The enzyme, as isolated from natural sources like rat medullary thyroid carcinoma is very costly.
Amidation may also by achieved by protease-catalysed condensation reactions using an amino acid amide or peptide amide as nucleophile. The yields of condensation reactions are generally low even in the presence of organic solvents unless the product precipitates in the reaction mixture and this is often not the case with long peptides. In addition, the precursor peptide may exhibit poor solubility in such media. However, serine or thiolprotease catalysed transpeptidation reactions may be carried out in high yield but it is a prerequisite that the enzyme exhibits specificity for a peptide bond close to the C-terminus. Endopeptidases are not generally suitable since they usually will cleave at other positions in the peptide chain as well. Serine carboxypeptidases, on the other hand, exhibit strict specificity for the Cterminal peptide bond and are able to catalyse the exchange of the C-terminal amino acid with an amino acid amide, added to the reaction medium to compete as nucleophile with water.
This property of serine carboxypeptidases was realized by a group of researchers at Carlsberg Research Center and lead to a family of patents assigned to the present assignee based on DK application No. 1443/79 represented by EP Patent No. 17485, US Patent No. 4.806.534 and its parent US patent No. 4.339.534 and WO 80/02151, which lead to i.a. DK Patent No. 155613. These patents were based on the at that time surprising finding that exopeptidases were suitable as catalysts for enzymatic peptide synthesis, while the prior art dealt exclusively with endopeptidases. Dependent on the nature of the reactants
- 3 (substrate and nucleophile components), and the reaction conditions, particularly the pH, serine and thiol carboxypeptidases may catalyze peptide synthesis by chain elongation or by transpeptidation. The preferred enzyme is carboxypeptidase Y (CPD-Y) from yeast.
The underlying and subsequent research has been further described in a number of articles (Ref 14-18), which together with the above-mentioned patents are all incorporated by reference.
The general principle of enzymatic peptide synthesis by transpeptidation in the presence of serine or thiol carboxypeptidases is disclosed in US Patent No. 4.806.473 and its parallel Danish Patent No. 155613. With particular reference to the production of peptide amides these patents generally disclose and claim the production of peptide amides A-B-NH^ where A represent an N-terminal protected amino acid residue or an optionally N-terminal protected peptide residue and B-represents an L-amino acid residue, by reacting as substrate component an optionally N-terminal protected peptide A-X-OH where A is as defined above and X represents an amino acid, with a nucleophile (amine) component H-B-NH2 in the presence of an L-specific serine or thiol carboxypeptidase enzyme from yeast, or of animal, vegetable or microbial origin in an aqueous solution of dispersion being a pH from 5 to 10.5. As further explained in Ref. 14 the preferred pH is about neutral if the formation of a peptide amide is desired.
As a representative example from US Patent No. 4,806,473 may be mentioned the reaction of Bz-Phe-Gly with Leu-W^ in the presence of CPD-Y at pH 7.6 and 25°C leading to the formation of Bz-Phe-Leu-N^ in a 90% yield. Further examples are incorporated in DK Patent No. 155 613 i.a. the reaction of Ac(Ala)^ with Leu-N^ in the presence of
CPD-Y leading to Ac(Ala)g-Leu-NH2 in a yield of 70%.
Further experiments are disclosed in Refs. 14-18 which support the pioneer character of these early patents and the general applicability of serine carboxypetidases as catalysts for C-terminal modification of peptides.
In order to provide a better understanding of the present invention which is described in more detail below a general discussion of the transpeptidation principle and the competing reactions is deemed proper.
C-terminal amidation of a peptide by means of a serine carboxypeptidase catalysed transpeptidation reaction is dependent on: a) solubility of the peptide in an aqueous medium in which the enzyme is active and relatively stable, b) accessibility of the C-terminus to enzymatic cleavage and c) availability of a serine carboxypeptidase of suitable substrate preference.
The type of reactions which may take place are outlined in Scheme 1 with the substrate R-NH-A-B-C-OH and the nucleophile H-D-NH2· The enzyme attacks the C-terminal peptide bond producing an acyl-enzyme intermediate which sub25 sequently may be deacylated by the nucleophile, producing an amidated transpeptidation product (TI), in competition with water, producing a hydrolysis product (Hl). The ratio of TI to Hl may be increased by increasing the concentration of the reactive, deprotonated form of the nucleo30 phile, i.e. by increasing either pH or the added amount of nucleophile. The nature of the leaving group, H-C-OH, has, in the case of CPD-Y, been shown to significantly
influence this ratio as well (14, 15) albeit with no obvious trend. Since this amino acid residue does not 35 constitute part of the desired amidated product (TI) it
may in principle be chosen freely.
A serine carboxypeptidase may also catalyse the formation of an elongated condensation product (Cl) in competition with Hl and Tl. However, at the optimal pH-values for transpeptidation such reactions are in aqueous solution energically unfavourable and consequently, at equilibrium, the amount of Cl which may be formed is limited to a few per cent, even at nucleophile concentrations exceeding 1 M. Furthermore, the rates of such reactions are normally very low compared to the competing attack on the Cterminal peptide bond, and thus, condensation products are rarely a problem. However, this relation may be reversed in cases where the C-terminal sequence of the peptide does not match the substrate preference of the enzyme with the consequence that small amounts of condensation products are formed in the initial phases of the reaction and then, with time, disappears as the substrate is consumed (16).
The hydrolysis product (Hl) may be transformed via the 20 same type of reactions into the products T2, H2 and Tl, followed by similar reactions with H2, etc. However, new
products may also arise when the enzyme acts on the Cterminal amide bond of Tl, i.e. ammonia functions as leaving group, producing another transpeptidation product (TT1) or hydrolysis product (HT1). For these products to appear in significant amounts it is required that the amidase activity towards Tl is significant compared to the peptidase activity towards the substrate and this is normally only the case at pH>9 where the peptidase activity is low and the amidase activity is high or in cases where the peptidase activity is low due to lack of preference for the C-terminal peptide bond.
It is apparent that the action of a serine carboxy35 peptidase on the C-terminus of a peptide in the presence of an amino acid amide may lead to numerous products of IE &11831 which only TI is the desired.
SCHEME I
CJ
Transpeptidation reaction c: Condensation reaction
- 8 While reactions with N-blocked dipeptides of a suitable composition relative to the substrate preference of the enzyme in some case lead to yields of TI approaching 100% (14, 15, 17, 18) the situation is different with larger molecules.
Thus in the patent family represented by US patent no. 4,645,740 and Danish patent no. 148714 assigned to the present assignee and incorporated herein by reference a process is described for enzymatic replacement of the B-30 amino acid in insulins, in particular conversion of porcine insulin into human insulin by replacement of the B-30 amino acid alanine with threonine using a serine carboxypeptidase, preferably carboxypeptidase Y from yeast (CPD-Y) or carboxypeptidase P from Penicillium janthinellum (CPD-P) as catalyst.
When porcine insulin was reacted with threonine amide in the presence of CPD-Y at pH 7.5 a complicated mixture of reaction products was obtained (Example 4 of the patents ) . The mixture was analysed by ion exchange chromatography and three peaks were detected. The peaks were further analyzed by enzymatic digestion and amino acid analysis leading to the following composition (Ins-Pro-Lys-Ala-OH being used to denominate the porcine insulin starting material), and the symbols from Scheme I are used as illustration.
Peak 1: 21% of which
65% Ins-Pro-Lys-Thr-Thr-NH2 (TTI)
% Ins-Pro-Lys-Thr-NH2 (TI)
Peak 2: 61% of which
52% Ins-Pro-Lys-Ala-OH (unreacted porcine insulin) (S)
26% Ins-Pro-Lys-Thr-OH (human insulin) (HT1)
22% Ins-Pro-Thr-NH2 (T2)
Peak 3: 18%
Breakdown products
Thus in the known process only 21% of a mixture of Tl and TT1 was obtained.
The predominant fraction consisted of a mixture of unreacted S, HT1 and T2.
Also a significant amount of breakdown products was obtained.
In another example carried out at pH 9.5 80% of the porcine insulin was reacted under formation of what appeared to be human insulin amide (Tl) which, however, was further hydrolyzed in situ to human insulin (HT1). A significant amount (20%) had reacted to form H2.
The above-mentioned insulin modification is further analyzed in Refs. 23 and 16.
While therefore the formation of human insulin amide by means of the general principle of transpeptidation described above (S -> Tl) is certainly possible, it is not easily monitored. Evidently reaction conditions may be selected which on the face of it seem favourable to the formation of Tl, but such attempts have not been reported.
- 10 Also the separation of the various reactants may be more or less difficult. As TI lacks the negative charge at the C-terminus it may easily be separated from Hl in preparative scale by ion exchange chromatography. However, provided that the side-chain of the C-terminal amino acid residue is uncharged, T2, T3 etc. as well as Cl and TT1 exhibit the same charge and can therefore not be separated from TI by ion exchange chromatography. In such cases preparative HPLC with reverse-phase columns appears to be the only, and a much less attractive, alternative. It is thus more desirable to attempt to suppress the formation of such products by selecting the optimal pH, concentration of nucleophile and most important, the serine carboxypeptidase of the most suitable substrate preference (see Table I) which rapidly and in the highest possible yield converts the substrate in TI and produces the lowest possible yield, if any, of the undesirable side-products.
To recapitulate the essence of the above observations, incorporation of C-terminal amide groups in peptides by transpeptidation in the presence of a serine carboxypeptidase using the proper amino acid amide as the nucleophile as broadly described and claimed in US patent no. 4,806,473 and the other family members is a very appropriate method virtually applicable for any peptide.
However, the process is not always sufficiently selective and necessitates purification procedures in order to remove products of various side reactions in particular when longer peptides are used, in which case the optimal reaction conditions for suppressing the side reactions are difficult to establish.
In the early articles by the original inventors published shortly after filing of the above patent applications, attempts were made to analyze the influence of the CIE 911831
- 11 terminal (leaving group) amino acid and the penultimate amino acid. Thus in Ref. 14 Breddam et al using Leu-NH2 as the nucleophile and Gly, Ala, Ser, Val, Leu and Phe as the leaving groups suggested on the basis of the obtained yields that only in cases where the leaving group is one of the smallest amino acids, i.e. Gly, Ala or Ser is the reaction successful, and at least for the simple substrates tested there was no dependence on the penultimate residue (being Ala, Phe and Gly).
In Ref. 15 Breddam et al using Gly-NH2 as the nucleophile and Z-Ala-X as the substrate, where X was Gly, Ala, Ser, Arg, Pro, Lys, Asn, His, Val, Met, Phe and Asp modified the earlier statement to the effect that when using Gly15 NH2 as the nucleophile, the yield is strongly dependent on the nature of the C-terminal (leaving group) amino acid. The yields varied from 10 to 100% with the lowest yields obtained with substrates where a hydrophobic acid (Val, Met, Phe) serves as leaving group. It should be noted that the yields with basic acids (Arg, Lys) are comparable to the yields with the hydrophilic acids (Ala, Ser), Lys being even better than Ser.
As for the penultimate amino acid residue of the peptide substrates the influence was investigated using a series of N-blocked dipeptides with different penultimate amino acids (Ala, Val, Leu, Ile, Phe and Val) as the leaving group. Using Gly-NH2 as the nucleophile, it was apparent that the coupling yield which varied from 45% for Ile to
% for Phe is dependent on the penultimate amino acid residue, but no obvious trend could be found.
In Ref. 23 some of the experiments underlying US patent no. 4,645,740 and its family members were discussed. Here porcine insulin Ins-Pro-Lys-Ala was reacted with i.a. ThrNH2 and it was concluded that Ins-Pro-Lys-OH was a better ,E 911831
- 12 substrate than Ins-Pro-Lys-Ala-OH, since Ins-Pro-Thr-NH2 was formed in greater yields than Ins-Pro-Lys-Thr-NH2. By inference Lys in this reaction was a better leaving group than Ala.
Also a significant oligomerization under formation of InsPro-Lys-Thr-Thr-NH2 occurred.
These results were further confirmed in Ref. 16 using Bz10 Lys-Ala-OH as a model peptide alongside with porcine insulin. The conclusive message was that for the future use of CPD-Y (the serine carboxypeptidase used in the experiments) in transpeptidation reactions it is important to be aware of the possibility that side products may be formed.
Besides the above investigations of the applicability of serine carboxypeptidases in C-terminal modifications of insulin, a further experiment with amidation of longer peptides using CPD-Y as a catalyst has been reported.
Thus in EP-B2-197794 and the parallel US patent no. 4,709,014 (Tamaoki) human calcitonin-Leu peptide was reacted with ammonia as the nucleophile using CPD-Y as the catalyst under conditions otherwise similar to those used by Breddam et al in Ref. 15. (The discussion of Ref. 15 above has been limited to the use of amino acid amides as nucleophiles, while in fact the main purpose of the article was to compare various nucleophiles also including ammonia).
Tamaoki obtained human calcitonin amide in a yield of
24.7%, leaving 57% unreacted substrate and 17.2% nonamidated side products (including human calcitonin).
In its more general aspects the Tamaoki patents disclose a
- 13 process for the preparation of a peptide having a Cterminal proline amide, which comprises reacting in aqueous solution a peptide substrate having C-terminal Pro-Leu, Pro-lie, Pro-Val or Pro-Phe with carboxypeptidase
Y in the presence of ammonia.
Without in any way wanting to endorse the statements made by Tamaoki, it should be mentioned that he claims that contrary to the findings of Breddam et al in Ref. 15, where a preference for hydrophilic C-terminal amino acids as leaving groups is expressed, the use of hydrophobic amino acids (Leu, Ile, Val and Phe) gives better yields than Gly, when Pro is the penultimate amino acid.
Nevertheless, the yields of the amidation products in Tamaoki's examples using Cbz-Ala-Pro-X-OH as the substrate, where X is Leu, Leu, Val, Phe and Ile, were only 35,1%, 43%, 15,4%, 13,4%, 22,6%, respectively. The remainder was - to the extent reported - unreacted starting material and non-amidated side-products Cbz-AlaPro-OH.
As mentioned earlier, the present invention relates to a process for the preparation of derivatives of growth hormone releasing factor and analogs thereof.
Growth hormone releasing factor (GRF) or somatocrinin, stimulating the release of growth hormone in the pituitary, is a 44-residue amidated peptide
- 14 5 10
H2N-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys15 20 25
Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gin-Asp5 30 35
Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg40
Gly-Ala-Arg-Ala-Arg-Leu-NH2 which may be used to stimulate growth of vertebrates (31). Both the amide group as well as the 15 amino acid residues closest to the C-terminus can be removed without abolishing the activity, but each results in a gradual decrease in the biological activity. However, a large part of the activity may be regained by amidation of these truncated peptides. One such derivative of particular interest is GRF (1-29)NH2, which can be regarded as the bioactive core of GRF.
Since the determination of the activity of GRF(1-29)NH2 numerous structural linear and cyclic analogs have been made by exchanging, deleting or modifying one or more of the 29 L-amino acids in the native GRF-chain.
Particularly interesting analogs have been made by Heimer et al (32), Roche Research Center, New Jersey, USA, viz. [desNH2Tyr1,D-Ala2,Ala15]-GRF(1-29)NH2 which is 10 times more potent than the parent compound in vivo and Cyclo(Asp8-Lys12)-[Ala15]GRF(1-29)NH2, which is less potent than the linear compound in vitro, but retained significant bioactivity and induced marked growth hormone in pigs.
The Heimer et al article is incorporated by reference.
Heimer et al also focused on a number of other modificaIE 911831
- 15 15 tions. Replacement of Gly with helix forming amino acids Val, Leu, Aib and Ala resulted in analogs with increasing biological activity, while replacement by Sar, a helixbreaking residue resulted in a profound loss of biological activity.
Analogs of GRF(1-29)NH„ with replacement of Tyr^ by z 2 desNF^Tyr .. or incorporation of D-Ala also resulted in increased biological activity. Other analogs are described in the patents and patent applications listed below, all incorporated herein by reference.
EP-A-352014 (Salk Inst, for Biol. Studies) showing a number of possible modifications of GRF and GRF(1-29)NH2 in the 1, 2, 3, 8, 12, 13, 15, 18, 21, 22, 24, 25, 27 and positions and where of interest in the present context 29
Arg may be replaced by Cys, Abu, Asp, Glu, Orn, Lys, Dab or Dap (all L or D). Ostensibly these peptides are more active with better resistance to enzymatic degradation than native GRF.
EP-A-307860 (Roche) describes a number of linear and cyclic GRF analogs related to the ones earlier discussed.
EP-A-292334 (Salk) describes a number of possible modifications of GRF and GRF(1-29)NH2 in the 1, 2, 3, 8,
, 12, 13, 15, 18, 21, 22, 24, 25, 27 and 28 positions.
FR-A-2594832 (Sanofi) describes modified GRF(1-29)NHO,
27 z where Val may be exchanged with Ile, Met may be
28 exchanged with Nle and/or Ser may be exchanged with Asn and in which at least 1 and up to 6 amino acids, preferably in positions 2, 5, 12, 17, 21 or 27, are replaced by an a-amino alkynoic acid , preferably a-amino-
4-pentynoic acid, a-amino-4-hexynoic acid and 2,6-diamino4-hexynoic acid, which may be substituted.
- 16 EP-A-216517 (Salk) corresponding to US-A-4689318 describes a number of GRF(1-29)NH2 analogs where at least 4 of amino acids 5-13, 15, 18-21 and 26 are different from the native 28 sequence and preferably containing Ala
US-A-4628043 (Salk) describes another group of analogs, where i.a. Tyr may be replaced by Met, Leu, D-Tyr, D-His 15 or His and Gly may be replaced by D-Ala.
Other analogs are described in EP-A-188214 (Tulane
Educational Fund) [D-Ala2,Arg12'21]GRF(1-29)NH2, EP-A177819 (Roche), US-A-4528190 (Salk), US-A-4518586 (Salk), 27
EP-A-121764 (Roche), with Met replaced by Leu or Nle,
JP-A-63/287799 (Tulane Educational Fund) disclosing i.a.
[iPr-Tyr1, iPr-Lys12'21]GRF(1-29)NH2 as 106 times more potent than GRF(1-29)NH2.
Generally speaking a person skilled in the art looking for a process for amidation of GRF(1-29)OH and its analogs would certainly expect the general process according to US patent no. 4,806,473 using GRF(l-28)-X, where X is an Lamino acid, as a substrate and Arg-NH2 as a nucleophile in the presence of a serine carboxypeptidase to work, but he would have no obvious choice of the applicable amino acids X, and he would expect a number of competing reactions to occur leaving him uncertain as to the yields and the necessary purification procedures in order to arrive at the desired amidated end-product.
The invention is based on the surprising finding that by selecting as the leaving group X in the starting material GRF(1-28)X a number of amino acids which does not logically fit into any of the preference patterns suggested in the earlier works by Breddam et al and Tamaoki discussed above, viz. the acyclic α-aminocarboxylic acids having an
- 17 uncharged hydrophilic side chain of at least the size of a methyl group, it is possible to obtain GRF(1-29)NH2 in a surprisingly high yield. Preferred amino acids are Thr, Ala, Ser, Gin and Asn, in particular Thr and Ala. Very small amounts of unreacted substrate and byproducts resulting from the competing reactions are observed, in particular when the experiences with human insulin amide described above and Tamaoki's results with calcitonin are taken into account.
To a certain extent, these observations are based on experiments with model tripeptides containing the native GRF(27-28) sequence and various leaving groups, as well as a synthetic GRF(1-28)Ala-peptide, as further described below.
Based on these experiments and the general correlation between model peptides and longer peptides shown in the above articles, it is therefore reasonable to conclude that the process is not limited to production of peptides containing the native GRF(l-29) sequence but also at least to analogs where one or more of the amino acids in positions 1 to 26 are replaced by other amino acids both in D- and L-form and cyclic amino acids, which may be protected or derivatized, e.g. analogs of the types disclosed in the above-mentioned patents incorporated by reference.
Accordingly, the present invention relates to a process for the preparation of derivatives of Growth Hormone Releasing Factor, viz. GRF(1-29)NH2 and analogs thereof, characterized by reacting a substrate component of the formula
GRF'-Met-Ser-X
- 18 wherein GRF' denominates the native GRF(l-26) sequence or analogs thereof including GRF(n-26) fragments, where n is from 1 to 8, and X is an acyclic a-amino carboxylic acid residue having an uncharged hydrophilic side chain of at least the size of a methyl group, with H-Arg-NH2 as nucleophile component in the presence of an L-specific serine or thiolcarboxypeptidase enzyme from yeast or of animal, vegetable or other microbial origin in an aqueous solution or dispersion having a pH of from 6 to 9, and if necessary coupling the desired N-terminal (l-(n-l)) fragment chemically or enzymatically.
For the enzymatic fragment coupling an endopeptidase enzyme may be used having the proper specificity with regard to the C-terminal of . the (l-(n-l)) fragment, e.g. papain or chymotrypsin.
A chemical fragment coupling may be carried out following introduction of suitable protective groups in solution phase in the presence of suitable catalysts, e.g. DCC together with additives, e.g. HOBt.
A preferred group of substrate components are those of the formula GRF-Met-Ser-X, wherein GRF denominates the native GRF(l-26) sequence, wherein from 1 to 4 of the amino acid residues may be replaced or deleted or the desa-NH2 derivatives thereof and X has the above meaning.
The applicable carboxypeptidases in the process of the invention are L-specific serine or thiol carboxypeptidases. Such enzymes can be produced by yeast fungi, or they may be of animal, vegetable or other microbial origin.
A particularly expedient enzyme is carboxypeptidase Y from yeast fungi (CPD-Y). This enzyme is described in the
- 19 earlier patents i.a. with reference to Johansen et al (Ref. 28) who developed a particularly expedient purification method by affinity chromatography on an affinity resin comprising a polymeric resin matrix with coupled benzylsuccinyl grups. CPD-Y, which is a serine enzyme is available in large amounts and displays relatively great stability. Further details are given in Ref. 14.
In addition to CPD-Y, which is the preferred enzyme at 10 present, the process of the invention is feasible with other carboxypeptidases, such as those listed in the following survey:
Enzyme
Carboxypeptidase S-l Carboxypeptidase S-2 Carboxypeptidase(s) from Carboxypeptidase(s) from
Origin
Fungi
Penicillium
Penicillium
Aspergillus
Aspergillus
Plants j anthinellum j anthinellum saitoi oryzae
Carboxypeptidase(s) C
Carboxypeptidase CN
Phaseolain
Carboxypeptidases M-I and M-II Carboxypeptidase W-II Carboxypeptidases from
Orange leaves
Orange peels
Citrus natsudaidai Hayata French bean leaves Germinating berlay Wheat bran
Germinating cotton plants
Tomatoes
Watermelons
Bromelain(pineapple)powder
The close relationship between a number of the above carboxypeptidases is discussed by Kubota et al (Ref. 33).
As stated above the process of the invention is carried out at pH 6.0 to 9.0, preferably at pH 6.5 to 8.0, most
- 20 preferably from 7.5 to 8.0. The preferred pH-value, which is often within a very narrow range, depends upon the enzyme used.
The selected pH-value should preferably be maintained throughout the reaction.
The pH-control may be provided for by incorporating a suitable buffer for the selected pH-range in the reaction medium.
The pH-value may also be maintained by adding an acid, such as HCl, or a base, such as NaOH, during the reaction. This may conveniently be done by using a pH-stat.
However, the conditions may also be influenced upon by varying the enzyme concentration, reaction time, etc.
The reaction is carried out in an aqueous reaction medium 20 which, if desired, may contain up to 80% by volume of an organic solvent. Preferred organic solvents are alkanols, e.g. methanol and ethanol, glycols, e.g. ethylene glycol or polyethylene glycols, glycerol, alkanoic acids, e.g. acetic acid, dimethyl formamide, dimethyl sulfoxide, tetrahydrofurane, dioxane and dimethoxyethane.
The selection of the composition of the reaction medium depends particularly upon the solubility, temperature and pH of the reaction components and the reaction products involved and upon the stability of the enzyme.
The reaction medium may also comprise a component that renders the enzyme insoluble, but retains a considerable part of the enzyme activity, such as an ion exchanger resin. Alternatively, the enzyme may be immobilized in known manner, e.g. by bonding to a matrix, such as a
- 21 cross-linked dextran or agarose, or to a silica, polyamide or cellulose, or by encapsulating in polyacrylamide, alginates or fibres. Besides, the enzyme may be modified by chemical means to improve its stability or enzymatic properties.
Preferably a chelating agent e.g. EDTA is included in the reaction medium which may also comprise salts.
The concentration of the two participants in the reaction may vary within wide limits, as explained below. A preferred starting concentration for the substrate component is 0,1-20 mM, preferably 1-10 mM, and for the nucleophile component 0.02 to 2 M, preferably 0.2 - 1.5 M.
The enzyme activity may vary as well, but the concentra-8 -4 tion is preferably 10 to 10 M. The most advantageous activity depends i.a. on the substrate chain and concentration, the nucleophile concentration, the reaction time, the reaction temperature, the pH, and the presence of organic solvents and/or salts. The amount of enzyme should in each case be adjusted to give the necessary degree of conversion for formation of an optimal absolute amount of product.
According to the invention the reaction temperature is 10° to 50°C, preferably 20° to 40°C. The most appropriate reaction temperature for a given synthesis can be determined by experiments, but depends particularly upon the concentration of the nucleophile component and the enzyme concentration. An appropriate temperature will usually be about 20° to 30°C, preferably about 25 °C, taking into account due consideration for enzyme activity and stability.
Similar variations occur for the reaction time which
- 22 depends very much upon the other reaction parameters, especially the enzyme concentration. The standard reaction time in the process of the invention is about 1-3 hours.
The abbreviations of amino acids, amino acid derivatives and peptides are according to Guidelines of the IUPAC-IUB Commission on Biochemical Nomenclature and the amino acids are on L-form unless otherwise stipulated. The binding site for the C-terminal amino acid residue of the sub10 strate is denoted ' and those for the amino acid residues in the amino-terminal direction away from the scissile bond are denoted S.^, S2, ...... Si . The substrate positions are all denoted P^', P^, P2 ..... P^ in correspondence with the binding sites (Ref. 1).
The following additional abbreviations are used: AcOH, acetic acid; Bz, N-benzoyl; DCCI, Ν,N'-dicyclohexylcarbodiimide; Dhbt, 3,4-dihydro-4-oxo-l,2,3-benzotriazin3-yl; DICI, diisopropylcarbodiimide; DMAP, 4-N,N-dimethyl20 aminopyridin, DMF, Ν,Ν-dimethylformamide; EDTA, ethylene diamine tetraacetic acid; Fmoc, fluorenyl-9-ylmethyloxycarbonyl; Ft, fraction of transpeptidation; GRF, growth hormone releasing factor; HPLC, high performance liquid chromatography; Mtr, 2,3,6-trimethyl-4-methoxyphenyl25 sulfonyl; Pfp, pentafluorophenyl; TFA, trifluoro acetic acid; THF, tetrahydrofuran.
Before the process of the invention will be illustrated by examples, starting materials, methods of measurement, etc.
will be explained in general terms.
Starting materials
DMF was purified by fractional distillation in vacuo. THF was passed through active Alumina prior to use. Fmoc-amino acids were purchased from Milligen and were converted into
- 23 Dhbt esters by reaction with carbodiimides and Dhbt-OH (Fluka) in THF (20). The peptide synthesis resin (Macrosorb SPR) was purchased from Sterling Organics. Sequence analysis was carried out on an ABI gas phase sequencer and d Durrum D-500 instrument was used for amino acid analysis. The HPLC equipment was from Waters Associates. Samples were hydrolyzed for 24 h in 6 N hydrochloric acid and evaporated, prior to amino acid analysis.
H-Arg-NH2-2HC1, Bz-Met-OH, other amino acids and amino acid derivatives and GRF (l-29)-NH2 were obtained from Bachem, Switzerland. CPD-Y is commercially available from the applicants. The substrates Bz-Met-Ser-Ala-OH, Bz-Met15 Ser-Leu-OH, Bz-Met-Ser-Thr-OH, Bz-Met-Ser-Arg-OH, Bz-MetSer-Gly-OH and Bz-Met-Ser-Ser-OH were synthesized as described below.. All other reagents and solvents were from Merck, W. Germany. CPD-W-II and CPD-S-1 were prepared as previously described (18, 21).
General procedure for the Preparation of Tripeptide
Substrates of the Formula BzMetSerX, X = Ala, Gly, Ser,
Thr, Leu, Arg, Asn, Gin, Met
.7 g benzoylmethionine methylester was dissolved in 240 ml DMF and 36.6 g serineisopropylester was added, followed by 400 ml H20. The pH was then adjusted to 8.5 using aqueous sodium hydroxide solution and 0.8 ml of 0.1 M EDTA was added. The reaction was then initiated by addition of
ml of a 0.2% (w/w) solution of crude papain preactivated by incubation with 0.1 M betamercaptoethanol at 35°C. The reaction was stirred for 3 hours and after 30 minutes 25 ml of enzyme solution was added and after one hour further 25 ml of enzyme solution was added. pH was then lowered to 3 by addition of aqueous HCl solution and the mixture was filtered and purified by reverse phase
- 24 HPLC on Waters Preppak 500 60 urn (?1θ columns using alcohol gradients at pH 3 in 50 mM acetic acid. Combined fractions containing the pure product benzoylmethionylserine isopropylester were combined and taken to dryness under reduced pressure to yield: 9.0 g BzMetSerOiPr (54%).
Example of Synthesis of BzMetSerThr:
2.0 g BzMetSerOiPr was dissolved in 30 ml of DMF and added to a solution of 24.0 g Threonine in 34 ml of H20 and 2 ml of 0.1 N EDTA in which pH had been adjusted to 9.0 using sodium hydroxide solution. The reaction was then initiated by addition of 2.8 ml of a 0.35 mM solution of CPD-Y and was stirred at constant pH for 4.5 hours at room tem15 perature. The reaction was then stopped by addition of 10 M HCl solution to pH 3 and following filtration, the mixture was purified by reverse phase HPLC on Waters Deltapak 300 A 15 urn C1g columns using an alcohol gradient in 50 mM acetic acid pH 3.
Combined fractions containing pure products were taken to dryness under reduced pressure to yield 0.63 g of BzMetSerThrOH (34%) with an analytical purity of more than 95% by HPLC at 220 nm.
BzMetSerAla, BzMetSerSer, BzMetSerGly, BzMetSerLeu, BzMetSerArg, BzMetSerAsn, BzMetSerGln and BzMetSerMet were prepared in an analogous manner, using the free amino acids Ala, Ser, Gly, Leu, Arg, Asn, Gin and Met as nucleophiles instead of Thr, respectively, and similarly pure products were obtained.
Assembly of human GRF(1-28)-Ala-0H
A column was packed with kiselguhr supported poly dimethyl acryl amide methyl ester resin, Macrosorb SPR-100 (500 mg, \£ 911831
- 25 0.05 mmole functional groups) derivatized with ethylene diamine and acylated with 4-hydroxylmethyl phenoxyacetic acid Dhbt ester. Fmoc-Ala-O-Pfp (137 mg, 275 umole) and DMAP (6 mg, 5 umole) was dissolved in DMF and recirculated through the resin (500 mg) overnight. The reaction mixture was displaced with DMF and acetic anhydride (50 ul) and DMAP (3 mg) was added. After 10 min of recirculation the reaction mixture was again displaced and the circuit was washed thoroughly with DMF.
A standard synthesis cycle consisted of a sequence of 10 min deprotection with piperidine in DMF (20%), a wash with DMF, the introduction and recirculation of acylating agent and a wash was entered at the deprotection point. During the washing periods all valves and loops were exercised. All couplings were performed with a single addition of Fmoc amino acid Dhbt esters (3 eqv. ) as described by Atherton et al. (20) with t-butyl based side chain protection and Mtr protection of arginine. Coupling times were determined by the fading of the intense yellow colour developed on the resin by formation of an ion pair between amino groups and Dhbt-OH (22). Two hours coupling time was sufficient for most of the reactions. Slow couplings were observed for Arg(20) (6 h) and for the sequence from
Ala(4) to Leu(14) 5-10 h).
Deprotection and cleavage from the resin was carried out by a 16 h treatment with TFA containing phenol (5%). Evaporation and trituration with diethyl ether (3 times 25 ml) resulted in isolation of the crude peptide (210 mg). This was analyzed by reverse phase HPLC (5 u Vydac) using a gradient of 30% to 70% of B (A = 0.1% TFA, B = 10% water and 0.1% TFA in acetonitrile). Two components in equal amounts were found, probably due to the presence of methionine sulfoxide in one of them. The peptide (200 mg) was treated with TFA containing thioanisole (10%) for 2
- 26 hours. After this, only one major component was found by analytical HPLC as described above. After evaporation and trituration with diethyl ether the peptide was dissolved in 10 ml DMF/1% AcOH (2/3, 10 ml) and chromatographed on a
G15 column with 1% AcOH. The fractions containing the major component was collected and lyophilized. This was separated by preparative HPLC on a 25 mm x 300 mm 15 u reversed phase column (Waters deltaprep.). The sample was divided into two portions each of which were dissolved in
ml 15% DMF in water. The sample was applied to the column and eluted at 10 ml/min first for 10 minutes with 30% B and then with a gradient (20% -70% B) over 30 min. The main peak eluted after 32 min and was collected and lyophilized to yield a total of 44 mg of peptide. The amino acid analysis showed: Asp 2.93; Thr 0.94; Ser 2.82; Glu 2.23; Gly 1.08; Ala 3.91; Val 1.05; Met 1.00; Ile 2.05; Leu 4.07; Tyr 1.67; Phe 0.90; Lys 2.16; Arg 2.31. The structure of the peptide was confirmed by gas phase sequence analysis.
Transpeptidation reactions
Transpeptidation reactions reported in table II below were carried out in the following way: the nucleophile (H-Arg25 NH2,2HC1) was dissolved in 5 mM EDTA and pH was adjusted with NaOH solution to the selected reaction pH. The substrate was then added (25 ul per 1 ml solution of nucleophile from a 40-80 mM solution in either DMF (the Bz-peptides) or 5% acetic acid (GRF(1-28)-Ala-0H), followed by enzyme from an aqueous solution. The reactions with the benzoylated tripeptides were carried out in a pH stat (1 ml) whereas the reactions with GRF(1-28)-Ala-OH were carried out in small scale (0.1 ml) with the nucleophile acting as buffer. When the substrate was added from 5% acetic acid a drop in pH was observed. To compensate, pH of the nucleophile solution was elevated prior to
- 27 addition of the substrate. These reaction conditions were slightly modified in the experiments reported in tables III and IV as explained below.
HPLC-analysis
During the reaction lOul aliquots were removed from the reaction mixture and the reactant composition was determined by HPLC. The following eluant system was used:
50 mM triethylammonium phosphate, pH 3.0 (A-buffer) and 50 mM triethylammonium phosphate, pH 3.0 in 80% CH^CN (Bbuffer) employing various linear and concave gradients. For the N-blocked tripeptides a Nova-Pak 5 μ C-18 reverse phase column from Waters was used whereas a Vydac C-18 reverse phase column was used for the GRF(1-28)-Ala-OH. A gradient was found which could separate the N-benzoylated tripeptide substrates as well as the possible products of the reaction including the by-products reported. This permitted a detailed analysis of the reaction mixture. A similar system was not developed for the longer peptides. However, maximal resolution was attempted and each product was collected and subjected to acid hydrolysis and amino acid analysis. The separations were carried out at room temperature and monitored by UV-absorbance at 254 nm (Bz25 peptides) or 280 nm (GRF).
The per cent composition of the reaction mixture was determined directly from the integrated peak areas since all components had the Bz- or, in the case of GRF, tyro30 sine as dominant chromophore at the respective wavelengths. The fraction of aminolysis (Ft) was expressed as the ratio between TI and all other products formed, i.e. uncomsumed substrate was disregarded in the calculation.
The invention is further illustrated in the accompanying drawings in which
- 28 Fig. 1: Time course of the CPD-Y catalysed transpeptidation on GRF(1-28)-Ala-OH using H-Arg-NH2 as nucleophile. The reaction conditions are listed in Table II.θ, GRF(1-28)-Ala-OH (S); Z\ ,
GRF( 1-29 )-NH2 (TI); |T| , GRF(l-28)-OH (Hl); \~^ ,
GRF(1-28)-Arg-Arg-NH2 (TTI).
Fig. 2: Separation of the products from GRF(1-28)-Ala-OH 10 after treatment with CPD-Y for 147 minutes in the presence of H-Arg-NH2. The separation was carried out on a Vydac C-18,5u column using the TEAP buffer system described above and a 30 to 45% B gradient over 30 minutes. 1: GRF(1-28)-Arg-Arg15 NH2, 2: GRF(1-29)-NH2, 3: GRF(1-28)-OH, 4: GRF(128)-Ala-OH.
RESULTS AND DISCUSSION
In the initial screening experiments the serine carboxypeptidase catalysed transpeptidation reaction leading to GRF (l-29)-NH2 was studied in model reactions with the following N-benzoylated tripeptides: Bz-Met-Ser-Arg-OH, Bz-Met-Ser-Leu-OH and Bz-Met-Ser-Ala-OH using H-Arg-NH2 as nucleophile. The transpeptidation product is in all three cases Bz-Met-Ser-Arg-NH2. corresponding to Bz-GRF (27-29)NH2. The initial choice of leaving groups was motivated by the high catalytic activity found from the expected hydrolytic preference of available serine carboxy30 peptidases as listed in Table I combined with their expected suitability in transpeptidation reactions. Thus Arg-OH was considered appropriate for CPD-W-II (17,21,26) and possibly CPD-S-1, for which good results had previously been obtained using also LeuOH as a leaving group with ArgNH2 as a nucleophile (18), while SerOH had performed poorly. Ala-OH and possibly Leu-OH were deemed
- 29 suitable for CPD-Y (14,15), from an activity standpoint (14,15). Regarding transpeptidation suitability of these groups, the prior art left no unambiguous or unequivocal guidelines for CPD-Y, as previously described. Thus, while in some references (14,15) the preferred leaving groups were small hydrophilic amino acid residues, other references (U.S. Patent 4,709,014) claimed a particular group of large hydrophobic amino acid residues, and Ala, which with respect to size and hydrophilicity pertains an intermediate position among the natural amino acids, had performed fairly poorly in the only report for a long peptide, i.e. Porcine insulin (U.S. Patent 4,645,740), where the overall yield was less than 10% of the correct product.
It should be noted in this respect, that hydrophilic amino acids are defined as amino acids having side chains more hydrophilic than cysteine, indicated by the hydrophilicity values assigned by Hopp and Woods (Proc. Nat. Acad. Sci. USA, 78 (6), pp. 3824-3828 (1981) (Ref initial results with Ala versus warranted further studies using hydrophilic amino acid residues (i.e. Gly, Ser, Thr, Asn and Gin) to establish the size requirements for possible successful product formation, and also an establishment of the degree of hydrophilicity needed by testing Met as leaving group, which has a hydrophilicity value between Leu and Ala.
34). The good Leu in this model different sizes of
- 30 Table I. Substrate preference of serine carboxypeptidases for hydrolysis of P-X-Y-OH peptide substrates.
X, Y CPD-Y CPD-W-II CPD-M-I CPD-S-1 _ _ _ _
Group (amino acids) P.^ P1' P^ P1' P.^ P^ ' P1 p '
7
Arg,Lys E D Glu,Asp Ε E Ser,Thr, Gin
Asn,His,Gly,Cys D D Tyr,Phe,Trp A A Ala,Met,Leu B A Val, Ile C A. Pro D D
A
E
D
B
C
D
E
A A
Ε E
D D
C A
C C
C D
Ε E
E A
C E
C E
B D
A C
A E
Β E
A
D
D
A
B
B
E
The preferences are listed accordingly to k +./K values in the following order: A > B > C > D > E, i.e. A corresponds to very fast hydrolysis and E to extremely slow hydrolysis.
The data are from Refs. 17, 18, 21, 26, 30.
The optimal conditions for serine carboxypeptidase catalysed transpeptidation reactions can be established by experiments in each case. The yield of transpeptidation is generally beneficially influenced by an increase in pH due to deprotonation of the amino group of the amino acid amide nucleophile but simultaneously the peptidase activity decreases, leading to lower rates of conversion, and the amidase activity increases, leading to degradation of the amidated product. An increase in pH can be com35 pensated by an increase in the concentration of nucleophile but this also reduces the rate of conversion since
- 31 the nucleophile acts as an inhibitor (25). With respect to pH the compromise usually is between 7.5 and 8.0 with the exception of CPD-S-1 which is unstable above pH 7.0.
The transpeptidation reaction with CPD-W-II and Bz-MetSer-Arg-OH was initially carried out at pH 7.6 and 10 mM H-Arg-NH2, the low concentration of nucleophile being motivated by the efficient binding of nucleophiles with positively charged side chains to this enzyme. After 47 minutes, 91% of the substrate had been converted into the following products (see Table II): 64% Bz-Met-Ser-Arg-NH2 (Tl), 20% Bz-Met-Ser-OH- (Hl) and 6% Bz-Met-OH (H2) . BzMet-Arg-NH2 (T2) as well as other potential products (see Scheme 1) were absent. The fraction of transpeptidation was 0.71 and this value was also obtained at pH 8.0. With 2, 5 and 25 mM H-Arg-NH2 the fractions of transpeptidation were 0.55, 0.64 and 0.72, respectively, suggesting that a value around 0.7 cannot be exceeded.
The transpeptidation reactions with CPD-Y on Bz-Met-SerAla-OH and Bz-Met-Ser-Leu-OH were initially carried out at pH 7.5 and 0.5 M H-Arg-NH2, a rather high concentration of nucleophile due to an expected poor binding to CPD-Y which has a preference for nucleophiles with hydrophobic side chains. The fraction of transpeptidation was 0.91 with BzMet-Ser-Ala-0H and only 0.41 with Bz-Met-Ser-Leu-OH. The general trend of dependence on the nature of the amino acid leaving group is consistent with those of the previous observations where the fraction of transpeptidation with CPD-Y in most cases has been significantly and sometimes drastically higher when the leaving group is small and/or hydrophilic, e.g. -Ala-OH, as compared with hydrophobic, e.g. -Leu-OH (14, 15). However, the yields for Leu is in contrast to the results reported in Ref. 14, p. 243, where Leu was used as a leaving group leading to a 0% yield of transpeptidation.
Thus, initially only the reaction with Bz-Met-Ser-Ala-OH was pursued at other reaction conditions and as basis for the further investigations of transamidation of longer peptides. At 0.025 M and 0.1 M H-Arg-NH2 the fractions of transpeptidation were lower, i.e. 0.77 and 0.87, respectively, and a concentration of 0.5 M was therefore maintained. However, in spite of the high fraction of transpeptidation at this concentration a small amount (2%) of the undesirable Bz-Met-Arg-NH2 (T2) was produced. An increase in pH to 7.8 prevented the formation of this product and simultaneously the fraction of transpeptidation was increased to 0.98.
CPD-S-1 was also tested in transpeptidation reactions with
Bz-Met-Ser-Arg-OH and Bz-Met-Ser-Leu-OH. With 0.2 M H-ArgNH2 and pH 6.5 the fractions of transpeptidation were 0.38 and 0.48, respectively. Higher concentrations of nucleophile had no beneficial effect.
The initial results of the transpeptidation reaction in the screening tests with the N-benzoylated tripeptides seemed to indicate that the most efficient amidation leading to a good yield of TI and suppression of the formation of undesirable peptides such as T2, could be achieved with
CPD-Y and with -Ala-OH as leaving group.
Consequently, GRF(1-28)-Ala-OH was selected as test intermediate and was prepared by continuous flow peptide synthesis. The assembly of GRF(1-28)-Ala-OH (2) was carried out by the solid phase methodology described above and cleaved from the resin by a 20 h treatment with TFA and phenol.
The reaction of GRF(1-28)-Ala-OH with CPD-Y in the presence of H-Arg-NH2 was carried out under the conditions stated in Table II. The reaction was followed by HPLC and
- 33 the time course is shown in Figure 1. After approximately 2 1/2 hours essentially all substrate had been converted into the products GRF(1-28)-Arg-NH2 (Tl), GRF(l-28)-OH (Hl) and GRF(1-28)-Arg-Arg-NH2 (TT1). The HPLC chromato5 gram of the final reaction mixture is shown in Figure 2. The identity of GRF(1-29)-NH2 as the dominant product was further investigated by co-chromatography with authentic GRF(1-29)-NH2: only a single peak was observed. Separate experiments with no H-Arg-NH2 added confirmed the reten10 tion time of Hl. Minor components eluting around the position of GRF(1-28)-Ala-OH, each constituting less than 2% of the reaction mixture, were collected but the amino acid analysis did not suggest any of them to be Cterminally modified derivatives of GRF(l-29).
At 147 minutes the reaction mixture contained 84% GRF(128)-Arg-NH2, i.e. GRF( 1-29)-NH2. Thus, with 1 g of CPD-Y approximately 2.7 kg of GRF(1-29)-NH2 can be produced using the reaction times and conditions listed in Table
II· However, CPD-Y is quite stable at pH 8.0 and 22°C and it is therefore possible to employ a much longer reaction time and correspondingly reduced enzyme concentration. Since CPD-Y is easily isolated from baker's yeast after autolysis (Ref. 28) or from the medium of genetically manipulated yeast cells (Ref. 29) the cost of the enzyme is rather low and the procedure described here therefore seems to be a valuable alternative to the use of the much more rare glycine oxidase.
ί- α. <-4 i—4 CN r-s p*. r*s o 0 0 in r4 CO O’ r-4 P's P's CO Ch cc r> OOOO Γ-S co 0 O 0 0 « XJ in O Z> 5< CN X CN cn 0 0 0 0000 O c 0 CN H OOO 0 O 0 0 0 CN CN CN O O V) r—4 O c-4 CO 00 »n σ\ x cp η- cn co O x CN CN 1—4 CN CN cn x i—4 o c= o r— O Ch O O’ υ H X X X cn CN 1—f co ν ιο CO σ> in 0 0 cn «-4 cn m co r*. x co cn X .-4 ΟΊ cn CN CN <- r-4 i-4 U-| O a φ L g c p-* χ o O cn <-4 O in 0 x cn P^ a ·—« cn cn CN CN co X CN Γ*» X <7 LJ Ξ 1—4 CN O «—1 CN 1-4 i—4 σι CJ Ό x 0 σ* 0 0 in n m in χ χ x O •r4 χ JJ P. P*» co 00 co X p*- vo S Ν Ν N X ex CJ Cl z^S. z—S z—S z-s. z—\ m z—s x—s z—s x—s z—S X—s X— r-4 xxx p** n* r-4 in cn 1-4 r-4 r-4 CN CN ω 000 0 O O O 0 OOOO O -a r-4 0 · O o Q e 000 O O O • 0 OOOO e P_, V v-x 's-χ x-x \-z \X >sX O 's·' S.X *«-/ 's-Χ O o ω 's-X — Ό Ξ 1—1 J4 1—) J4 1-4 S_z Η Η H H4 H4 r-4 r-4 5 1 1 1 1 1 333 3 3 X >» cn >- > J > >* z—S C\ 04 CN Zm 1 z /—» r-4 1 y* 0 0 x CN n 0 0 0 0 0X0 0 SX CO g «—4 r—X CN 0 0 0 0 0 CN 0 0 U- J4 CN m cn x r-4 m in OC r-4 O 04 O X\ z—s z—\ z—S. x—s x-s z—\ z—s. z—x z—> z—s. z—s z—« c .-4 1—4 r—1 r-4 r*4 CN CN CN CN CN CN CN CN o ν_Χ S.-Z S«Z \-z s-X V_z* 's-Χ ’s-Χ 's-Χ 's-Χ x-x s_z S»z .-4 X u X X 0 0 1 < t 1 1 0 · 1 1 1 1 X T3 1 1 0 •—4 z—' bO 3 ca 1 e w Φ r-4 to < £3 < · 1 1 1 J , 1 1 1 1—4 « 1 1 < J4 J4 J4 • CJ Φ Φ Φ z— 1-4 4J X » · < ί t X « X * » » co 1—1 ta ( 1 1 CN L u u 4-J • φ XJ Φ Φ Φ r-4 r-4 w z · · t « 1 z > z · > s— JO Xf « U- «a 3 N N N C6 H X X · < » « • X > co 1 > 1 0
All reactions were carried out in the presence of 5 wm EDTA.
4) Amino acid analysis suggested that this product corresponded to GRl?(l-28)-Arg-Arg-NH
As mentioned earlier the initial results with the Nbenzoylated tripeptides Bz-Met-Ser-Ala-OH, Bz-Met-Ser-ArgOH and Bz-Met-Ser-Leu-OH seemed to indicate that among these three model peptides the most efficient amidation would be achieved with Ala-OH as the leaving group, and this approach was tested further with the complete peptide sequence. In order to get a more thorough analysis of the appropriate leaving groups for the amidation a further series of model peptides containing hydrophilic amino acids of different size as leaving group were synthesized. Thus the small Gly, the intermediate Ser and the larger Thr were chosen, and transpeptidation tests were carried out using Bz-Met-Ser-Ala-OH as comparison.
The results appear from Table III below.
Table III
Substrate CPD-Y Time Composition %
mg/ml min. S TI Hl Others Ft BzMetSerAlaOH 0.06 64 10.4 76.9 9.1 3.6 0.86 BzMetSerSerOH 0.62 51 17.0 61.0 3.1 18.0 0.74 BzMetSerGlyOH 1.23 89 13.6 48.3 1.5 36.6 0.56 BzMetSerThrOH 0.10 94 10.8 72.9 8.0 8.4 0.82
Concentration of substrate: 2mM Concentration of ArgN^: lOOOmM pH: 7.90
It is seen that as far as product yield and fractions of transpeptidation are concerned, surprisingly Thr which has not earlier been reported as leaving group is comparable to Ala despite its larger size. Despite a higher enzyme concentration Ser leads to somewhat less selective reac36 tion while Gly leaves a greater amount of unreacted substrate and a significant amount of byproducts.
In some of the reactions of the method according to the 5 present invention, the absolute amount of product formed depends on the degree of conversion and passes through an optimum, which would justify stopping the reaction and recycling the remaining substrate, while in others, running the reaction to virtual completion is fully justified. In the Bz-Met-Ser-X tripeptide model experiments performed, Ala and Thr as the leaving groups X appear to be in the latter category, while Asn and Gin as leaving groups would appear to be in the former. In Table IV below some results at incomplete conversion are listed
using the example: large, but hydrophobic Met as a reference TABLE IV 20 Substrate CPD-Y Time Composition mg/ml min. S TI Hl Others Ft
BzMetSerAsnOH 1.60 52 47.0 40.0 3.0 10.0 0.76 BzMetSerGlnOH 1.30 38 29.0 52.6 4.4 15.0 0.73 25 BzMetSerMetOH 0.03 25 30.0 32.2 33.0 4.8 0.46
Concentration of substrate: 2 mM, concentration of ArgNH^: 1000 mM, pH: 7.9
It is seen that, at between 50% and 70% conversion, good amounts of product are formed relative to the amount of substrate consumed using the large, hydrophilic amides Asn and Gin as leaving groups, while Met performs as poorly as
Leu and Gly in Tables II and III and gives rise to a lot of hydrolysis byproduct. It is to be noted that this is in
- 37 spite of the fact that, as stated in Table I, where Met is grouped together with Leu and Ala, Met is an active substrate as a leaving group, reducing the enzyme requirement as apparent from Table IV. It can be noted that Table I also groups Ser, Thr, Gin and Asn together with Gly as leaving groups, but in a completely different category than Ala, Leu, Met. Thus, the results in Tables II, III and IV illustrate the lack of possibility to predict the synthetic yields solely based on the hydrolytic preferences listed in Table I.
A logical standard for evaluation of the applicability of the various possible leaving groups would be the native GRF sequence, in which the C-terminal sequence is -Met15 Ser-Arg-OH.
Based on the above results it can be concluded that a transamidation can be carried out with a sufficient selectivity using Ala, Thr, Ser, Asn and Gin as the leaving groups, while Leu, Gly and Met give rise to a significant amount of byproducts. It thus appears that a hydrophilic side-chain of at least the size of a methyl group is necessary for the desired selectivity and improved yield over the native GRF sequence. This result could not be foreseen from the articles discussed above and indicate that it is indeed possible to select substrates having greater feasibility as intermediates for transamidation than the natural GRF (1-29).
Claims (8)
- CLAIMS : 1. Process for the preparation of derivatives of Growth Hormone Releasing Factor, viz. GRF(1-29)NH 2 and analogs 5 thereof, characterized by reacting a substrate component of the formula GRF'-Met-Ser-X wherein GRF' denominates the native GRF(1-26) sequence or analogs thereof including GRF(n-26) fragments , where n is from 1 to 8, and X is an acyclic β-amino carboxylic acid residue having an uncharged hydrophilic side chain of at 15 least the size of a methyl group, with H-Arg-NH 2 as nucleophile component in the presence of an L-specific serine or thiolcarboxypeptidase enzyme from yeast or of animal, vegetable or other microbial origin in an aqueous solution or dispersion having a pH of from 6 to 9, and if 20 necessary coupling the desired N-terminal (l-(n-l)) fragment chemically or enzymatically.
- 2. The process according to claim 1, wherein the substrate component used is GRF-Met-Ser-X, wherein GRF denominates 25 the native GRF(l-26) sequence, wherein from 1 to 6 of the amino acid residues may be replaced or deleted or the desa-NHj derivatives thereof and X has the above meaning.
- 3. The process according to claims 1 or 2, wherein X is 30 selected from Ala, Ser, Thr, Asn and Gin.
- 4. The process according to claims 1 to 3, wherein the carboxypeptidase enzyme used is carboxypeptidase Y from yeast.
- 5. The process according to claim 4, wherein a carboxyΕ 911831 peptidase Υ is used which has been purified by affinity chromatography on an affinity resin comprising a polymeric resin matrix with a plurality of coupled benzylsuccinyl groups .
- 6. The process according to any of claim 1 to 3, wherein the carboxypeptidase enzyme used is selected from the group consisting of Carboxypeptidase S-l and S-2 from Penicillium janthinellum, carboxypeptidases from Aspergillus saitoi or Aspergillus oryzae, carboxypeptidases C from orange leaves or orange peels, carboxypeptidase C N from Citrus natsudaidai Hayata, phaseolain from bean leaves, carboxypeptidases M-I and M-II from germinating barley, carboxypeptidase W-II from wheat bran, carboxypeptidases from germinating cotton plants, tomatoes, watermelons and Bromelein (pineapple) powder.
- 7. The process according to any of the preceding claims, wherein an immobilized carboxypeptidase enzyme is used.
- 8. The process according to any of the preceding claims, wherein an aqueous reaction solution containing from 0 to 80% of organic solvent is used. 25 9. The process according to claim 8, wherein the organic solvent used is selected from the group consisting of alkanols, alkanoic acids, dimethyl sulfoxide, dimethyl formamide, dioxane, tetrahydrofurane, dimethoxy ethane, glycerol, ethylene glycol and polyethylene glycols. 10. The process according to claim 1, wherein a GRF'-MetSer-X is used, which has been produced enzymatically, by recombinant DNA-methods, by chemical synthesis or a combination of these. Ε911831 - 40 11. A GRF-related peptide of the formula GRF-Met-Ser-X 5 wherein GRF denominates the native GRF(l-26) sequence, wherein from 1 to 4 amino acid residues may be replaced or deleted or the des-a-NH 2 derivatives thereof, and X is an acyclic α-aminocarboxylic acid residue having an uncharged hydrophilic side chain of at least the size of a methyl 10 group. 12. A GRF related peptide according to claim 11, wherein GRF denominates the native GRF(l-26) sequence and X has the above meaning. 13. A GRF related peptide according to claim 11 or 12, wherein X is Ala, Thr, Ser, Asn or Gin. 14. A GRF related peptide according to claim 13, wherein X 20 is Ala or Thr. - 41 15. A process for the preparation of derivatives of Growth Hormone Releasing Factor, namely GRF(1-29)NH2 and analogs thereof, substantially as herein described with reference to the accompanying drawings. 16. A GRF-related peptide according to Claim 11, substantially as herein described with reference to the accompanying drawings. 10 17. The features described in the foregoing specification, or any obvious equivalent thereof, in any novel selection. - 42 5 REFERENCES: 1. Schechter, I. & Berger, B. (1967) Biochem. Res. Commun. 27, 157-162 Bhiphys, 14. Breddam, K., Widmer, F. & Johansen, J.T. Carlsberg Res. Commun. 45, 237-247 (1980) 15. Breddam, K., Widmer, F. & Johansen, J.T. Carlsberg Res. Commun. 46, 121-128 (1981) 16. Breddam, K., Johansen, J.T. & Ottesen, M. Carlsberg Res. Commun. 49, 457-462 (1984) 17. Breddam, K. (1985) Carlsberg Res. Commun. 50, 309-323 18. Breddam, K. (1988) Carlsberg Res. Commun. 53, 309-320 19. 20. Atherton, E., Holder, J.L., Meldal, M., Sheppard, R.C. & Valerio 2887-2894 , R.M. (1988) J. Chem. Soc. Perkin Trans. 1, 21. Breddam, K. S0rensen, S. B. & Svendsen, I. (1987) Carlsberg Res. Commun. 52, 297-311 23. Breddam, K., Widmer, F. & Johansen, J.T. (1981) Carlsberg Res. Commun. 46, 361-372 25. Breddam, K. & Ottesen, M. (1984) Carlsberg Res. Commun. 49, 473-481 26. Breddam, K. , S0rensen, S.B. & Ottesen, M. (1985) Carlsberg Res. Commun. 50, 199- 209 28. Johansen, J.T ., Breddam, K. & Ottesen, M. (1976 ) Carlsberg Res . Commun. 41, 1-14 29, Nielsen, T.L. , Holmberg, S. & Petersen, J.G.L. Appl. Microbiol. Biotechnol. (in print) 30. Breddam, K., S0rensen, S.B. & Ottesen, M. (1983) Carlsberg Res. Commun. 48, 217-230 31. Brain Peptides, Ed. Krieger, Brownstein, Martin, John Wiley & Sons (1983), 976-980 32. Synthetic peptides: Approaches to Biological Problems, Heimer et al, alan R. Liss, Inc. (1989) 309-319 33. Kubota et al. Carboxypeptidase (1973), J. Biochem. 74, no. 4, 757-770 34. Hopp and Woods, Proc.Nat.Acad.Sci. USA, 78 (6), pp. 3824-3828 (1981)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK133990A DK133990D0 (en) | 1990-05-30 | 1990-05-30 | PROCEDURE FOR PREPARING GROWTH HORMONE RELEASING FACTOR (GRF) DERIVATIVES USED AS INTERMEDIATES IN THE PROCEDURE |
Publications (1)
Publication Number | Publication Date |
---|---|
IE911831A1 true IE911831A1 (en) | 1991-12-04 |
Family
ID=8103761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE183191A IE911831A1 (en) | 1990-05-30 | 1991-05-29 | Process for the preparation of derivatives of growth hormone¹releasing factor and peptides useful as intermediates in the¹process |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0537185A1 (en) |
AU (1) | AU647796B2 (en) |
CS (1) | CS163191A3 (en) |
DK (1) | DK133990D0 (en) |
IE (1) | IE911831A1 (en) |
IL (1) | IL98313A0 (en) |
WO (1) | WO1991018998A1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6339237B2 (en) * | 1979-04-06 | 1988-08-04 | Karuruberugu Baiotekunorojii Ltd As |
-
1990
- 1990-05-30 DK DK133990A patent/DK133990D0/en not_active Application Discontinuation
-
1991
- 1991-05-29 EP EP91910581A patent/EP0537185A1/en not_active Withdrawn
- 1991-05-29 WO PCT/DK1991/000143 patent/WO1991018998A1/en not_active Application Discontinuation
- 1991-05-29 AU AU79092/91A patent/AU647796B2/en not_active Expired - Fee Related
- 1991-05-29 IE IE183191A patent/IE911831A1/en unknown
- 1991-05-30 IL IL98313A patent/IL98313A0/en unknown
- 1991-05-30 CS CS911631A patent/CS163191A3/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU7909291A (en) | 1991-12-31 |
IL98313A0 (en) | 1992-06-21 |
CS163191A3 (en) | 1992-02-19 |
DK133990D0 (en) | 1990-05-30 |
EP0537185A1 (en) | 1993-04-21 |
AU647796B2 (en) | 1994-03-31 |
WO1991018998A1 (en) | 1991-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3505533A1 (en) | Synthesis method for low-racemization impurity liraglutide | |
CA2623547C (en) | Method for amidating polypeptides with basic aminoacid c-terminals by means of specific endoproteases | |
CN101068833B (en) | Method for producing carboxy-terminal amidified peptides | |
JPS6339237B2 (en) | ||
JPS62500560A (en) | alpha amidation enzyme | |
US4645740A (en) | Process for enzymatic replacement of the B-30 amino acid in insulins | |
Breddam et al. | Amidation of growth hormone releasing factor (1–29) by serine carboxypeptidase catalysed transpeptidation | |
Kreil | [21] Occurrence, detection, and biosynthesis of carboxy-terminal amides | |
AU660944B2 (en) | Process for the preparation of C-terminally amidated peptides | |
US5580751A (en) | Process for the preparation of C-terminally amidated peptides | |
US5612454A (en) | Process for purification of polypeptide using a buchner funnel | |
AU647796B2 (en) | An enzymatic process for the preparation of derivatives of growth hormone releasing factor and peptides useful as intermediates in the process | |
CN112759653B (en) | PKEK fusion protein and preparation method and application thereof | |
Groeger et al. | Papain‐catalyzed synthesis of dipeptides | |
SAKINA et al. | Thermolysin-catalyzed synthesis of peptide amides | |
TWI331630B (en) | Saponin-decomposing enzyme, gene thereof and large-scale production system f or producing soyasapogenol b | |
Fortier et al. | Substrate-and stereo-specificities in clostripain-catalyzed peptide synthesis | |
EP2167673B1 (en) | Process for the conversion of c-terminal peptide esters or acids to amides employing subtilisin in the presence of ammonium salts | |
CA2451528C (en) | Novel aminopeptidase derived from bacillus licheniformis, gene encoding the aminopeptidase, expression vector containing the gene, transformant and method for preparation thereof | |
GB2220938A (en) | Use of PAM enzyme in solid phase peptide synthesis | |
AU773483B2 (en) | Novel protein, gene encoding the protein and process for preparing the protein | |
EP0662482A1 (en) | Process for preparation of human glicentin | |
WO1992015695A1 (en) | Process for the c-terminal modification of peptides having a c_terminal penultimate proline residue | |
JP3353052B2 (en) | Peptide synthesis method using enzymes | |
Bongers et al. | Enzymatic Semisynthesis of Growth Hormone-Releasing Factor and Potent Analogs |